Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study
暂无分享，去创建一个
M. Marazuela | A. Lamarca | J. Valle | R. García-Carbonero | J. Capdevila | E. Grande | P. Jiménez-Fonseca | J. Gallego | Á. Castaño | J. Barriuso | G. Crespo | F. Vilardell | P. Escudero | T. Alonso-Gordoa | A. Carmona-Bayonas | M. Benavent | V. Alonso | M. Riesco-Martinez | A. Custodio | M. Sánchez Cánovas | J. Hernando Cubero | C. Lopez | A. Lacasta | A. Fernández Montes | J. Díaz | E. Feliciangeli | M. Llanos | A. Segura | J. C. Percovich | A. Castaño